We are currently investigating BPL-003 (our novel intranasal formulation of 5-MeO-DMT) and ELE-101 (our novel intravenous formulation of psilocin) for Treatment Resistant Depression, Major Depressive Disorder and Alcohol Use Disorder.
Condition
Status
Product
Phase
Sex &Â age range
Location(s)
Link
Treatment Resistant Depression
Recruiting
BPL-003
IIb
M + F
18 – 75 years
Australia, Germany, Poland, Spain, UK, US
Treatment Resistant Depression
Recruiting
BPL-003
IIa
M + F
18 – 75 years
London, UK
Alcohol Use DisorderÂ
Rec. Completed
BPL-003
IIa
M + F
18 – 64 years
London, UK
Contact
Major Depressive Disorder
Rec. Completed
ELE-101
IIa
M + F
18 – 65 years
Manchester, UK, Liverpool, UK
Treatment Resistant Depression
Rec. Completed
BPL-003
IIa
M + F
18 – 65 years
London, UK
Liverpool, UK
Phase IIb study of BPL-003 in patients with Treatment Resistant Depression
Recruiting
This randomised, dose-finding study will evaluate the effects of a single medium or high dose of BPL-003 against a sub-perceptual dose in patients with Treatment Resistant Depression (TRD). TRD is defined as a failure to respond to two or more pharmacological treatments within the current depressive episode. It is taking place at approximately 40 sites across Australia, Germany, Poland, Spain, the United Kingdom and the United States.
Phase IIa study of BPL-003 in patients with Treatment Resistant Depression
Recruiting
This open-label Phase IIa study is taking place at Hammersmith Medicines Research in London and MAC Clinical Research in Liverpool and will assess the safety, tolerability, efficacy and pharmacokinetics of a two-dose administration of BPL-003 in patients with Treatment Resistant Depression (TRD) who are not taking SSRIs. TRD is defined as a failure to respond to two or more pharmacological treatments within the current depressive episode.
Phase IIa study of BPL-003 in patients with Alcohol Use Disorder
Recruitment Completed
This open-label Phase IIa study is taking place at King’s College and Clerkenwell Health in London, and will investigate the safety and efficacy of a single dose of BPL-003 alongside an abstinence-oriented cognitive behavioural psychological intervention in patients with Alcohol Use Disorder.Â
Phase IIa study of ELE-101 in patients with Major Depressive Disorder
Recruitment Completed
This open-label Phase IIa is taking place in Manchester and Liverpool and will assess the safety, tolerability, subjective effects and efficacy of a single dose of ELE-101 in patients with depression.
Phase IIa study of BPL-003 in patients with Treatment Resistant Depression currently taking SSRIs
Recruitment Completed
This open-label Phase IIa study is taking place at Hammersmith Medicines Research in London and will assess the safety, tolerability, efficacy and pharmacokinetics of BPL-003 co-administration in patients with Treatment Resistant Depression who are also taking citalopram, escitalopram, fluoxetine or sertraline.
Links to other websites do not imply affiliation or endorsement. 51³Ô¹ÏÍø does not control and is not responsible for their content.
